SCHEMBL342127

SCHEMBL342127

O=C(O)CN(CC(=O)O)c1ccc(C(=O)O)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.52
TP53 P04637 1/20 0.52
SRD5A2 P31213 3/20 0.46
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA12 O43570 1/20 0.44
CA3 P07451 1/20 0.44
TYR P14679 1/20 0.44
DRD1 P21728 1/20 0.44
CA4 P22748 1/20 0.44
CA6 P23280 1/20 0.44
CA5A P35218 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
CA5B Q9Y2D0 1/20 0.44
MEN1 O00255 1/20 0.44
NPC1 O15118 1/20 0.44
POLB P06746 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8038936 0.89 TDP1 (0.44) TSHRDRD1MEN1NPC1KMT2A
SCHEMBL4127840 0.88 ALDH1A1 (0.47) TSHRTP53MEN1NPC1POLB
SCHEMBL472319 0.84 TSHR (0.55) TSHRTP53SRD5A2CA1CA2
SCHEMBL18360379 0.83 MAPT (0.53) MEN1NPC1POLBKMT2AALDH1A1
SCHEMBL13645018 0.80 CA2 (0.46) CA1CA2CA12CA3TYR
SCHEMBL202173 0.79 TDP1 (0.50) TSHRMEN1NPC1POLBKMT2A
SCHEMBL3763384 0.79 NPC1 (0.50) TSHRTP53SRD5A2CA1CA2
SCHEMBL2806419 0.79 TSHR (0.48) TSHRTP53SRD5A2CA1CA2
SCHEMBL653865 0.79 TSHR (0.52) TSHRCA1CA2CA12CA7
SCHEMBL7631517 0.79 AKT1 (0.52) TP53MEN1NPC1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8968711-B2 Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process L'OREAL (FR) 2015-03-03 US claimed
US-8822390-B2 Scale inhibitor CLARIANT FINANCE (BVI) LIMITED (VG) 2014-09-02 US claimed
EP-2556130-A1 SCALE INHIBITOR Clariant Finance (BVI) Limited (VG) 2013-02-13 EP claimed
EP-2371923-B1 Scale inhibitor CLARIANT FINANCE BVI LTD (VG) 2013-02-13 EP claimed
US-20130023449-A1 Scale Inhibitor CLARIANT FINANCE (BVI) LIMITED (VG) 2013-01-24 US claimed
WO-2011120655-A1 SCALE INHIBITOR CLARIANT INTERNATIONAL LTD (CH) 2011-10-06 WO claimed
EP-2371923-A1 Scale inhibitor Clariant International Ltd. (CH) 2011-10-05 EP claimed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 US claimed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 US claimed
EP-1975707-B1 Curable composition and planographic printing plate precursor FUJIFILM CORP (JP) 2017-07-19 EP disclosed
EP-1801651-B1 Polymerizable composition and planographic printing plate precursor using the same FUJIFILM CORP (JP) 2017-04-19 EP disclosed
EP-2471655-B1 Lithographic printing plate precursor and lithographic printing method FUJIFILM CORP (JP) 2016-08-17 EP disclosed
EP-1887423-B1 Laser-decomposable resin composition and pattern-forming material using the same FUJIFILM CORP (JP) 2016-01-27 EP disclosed
EP-1431032-B1 Polymerizable composition and lithographic printing plate precursor FUJIFILM CORP (JP) 2015-12-09 EP disclosed
EP-0618346-B1 Placing a scale inhibitor within a brine-containing subterranean formation SHELL INT RESEARCH (NL) 1997-07-23 EP disclosed
US-5629354-A Photopolymerization initiator system comprising a spectral sensitizer and a polycarboxylic acid co-initiator EASTMAN KODAK COMPANY (US) 1997-05-13 US disclosed
EP-0765913-A1 Process for the preparation of lactic acid-based polyester compositions DAINIPPON INK AND CHEMICALS, INC. (JP) 1997-04-02 EP disclosed
EP-0730201-A1 Sensitized photopolymerizable compositions and use thereof in lithographic printing plates EASTMAN KODAK COMPANY (US) 1996-09-04 EP disclosed
EP-0618346-A2 Placing a scale inhibitor within a brine-containing subterranean formation SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1994-10-05 EP disclosed
US-5346010-A Precipitation of scale inhibitors in subterranean formations SHELL OIL COMPANY (US) 1994-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS CUTA, SUCLG1, KRT18 TSHR 4385/4885TP53 964/4885SRD5A2 919/4885
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT ACMSD, CUTA, PCCA TSHR 2885/4885TP53 1009/4885SRD5A2 343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.